New Third Board TOP10 Pharmaceuticals | 100 billion market value, billions of revenue...

Medical Network September 28th In recent years, the rapid development of the New Third Board has once witnessed a spurt of growth. With the continuous improvement of relevant policies, the number of enterprises listed on the New Third Board has grown from quantity to quality, and high-quality enterprises have gradually surfaced. In the pharmaceutical industry, in the first half of the year, Tianshi Marketing achieved a unique profit of 5.6 billion yuan; Chengda Bio, Heping Pharmaceuticals' net profit exceeded 250 million. In addition, Forbes China released 2018 China New Third Board Enterprise TOP100, a total of 6 Home pharmaceutical companies are on the list. From the perspective of market stratification, the innovation layer is only Chengda Bio and Hefei Pharmaceutical.

As of September 26, 2018, the New Third Board was listed. enterprise There are 10,950 in total, of which 1,162 are market-transferred and 9788 are auctioned. In 2016, the New Third Board launched a tiered management pilot scheme to divide the market into innovation and foundation. Currently, 934 enter the innovation layer, 10016. In the basic layer. In the pharmaceutical industry, in the first half of the year, Tianshi Marketing was the only one with 5.6 billion in revenue; Chengda Bio, the total net profit of Heping Pharmaceuticals exceeded 250 million.

TOP10 of the New Third Board Pharmaceutical Enterprises in the first half of 2018 (Unit: 10,000 yuan)

Recently, Forbes China released 2018 China's new three-board enterprise TOP100. The list is based on revenue, net profit, total market capitalization, ROA, and ROE. Among them, there are 6 pharmaceutical companies in the list, which are stratified from the market. 2. In terms of innovation, there are only two large and two integrated medicines.

2018 Forbes China New Third Board TOP100 list of pharmaceutical companies (Unit: 10,000 yuan)

Note: The rankings are in no particular order

Tianshi Marketing is a subsidiary of Tasly. It was listed on the New Third Board in August 2017. Its main business is drug , medical instruments , Health care products Distribution and distribution of products, retail chain and chronic disease management and pharmaceutical value-added services, for Tasly Biology medicine Industrial layout and upgrade play an important role.

2015, operating income scale in 2016 with days of marketing are more than ten billion yuan in the first half of this year, its operating income 560,053.07 million, an increase of 16.76%, attributable net profit of 2,809.87 million yuan, down 19.34 percent year on year, non-profit buckle 2,096.95 million. among them, a distribution ratio of the total revenue of nearly 90%, amounting to 497,167.76 million, an increase of 16.76%.

It is understood that, with days of marketing April 13, 2018 to achieve to make transfer transactions City, May 25 shortlisted three new board innovation layer 2018, greatly enhance the activity and access to equity finance transactions. At the same time, to be issued should be adopted accounts receivable asset financing special programs to support not more than 1.7 billion yuan, in order to improve capital efficiency, optimize the asset structure, reduce financial risk. Tasly marketing through building 'product + shipping + talents' full resource platform, tamp in Shanxi Province business base in Guangdong province, with the gradual rich variety and distribution terminal resources to further speed up the direct business customers in other parts of the development efficiency, expand the scale and distribution network.

SynTheAll Pharmaceutical in April 2015 in the three new board listed as a subsidiary of WuXi its business into bulk drugs and formulations CDMO business CDMO business services mainly for multinational pharmaceutical companies and biopharmaceutical companies; major pharmaceutical services The type is innovative medicine, namely, New Molecular Entity (NME, New Molecular Entity); the main medical treatment areas include anti-cancer, anti-AIDS, anti-hepatitis C, hypolipidemic, analgesic, etc. In the first half of the year, the company's operating income was 1,121,201,700 yuan. , a year-on-year increase of 19.29%, a net profit of 266,569,600 yuan, an increase of 11.35%, a non-net profit of 275,503,100 yuan, an increase of 22.31%. Hequan said that the performance growth is mainly through cooperation with customers in the preclinical stage Relationships, continuous introduction of new clinical phase III, and commercialization projects, boosting the company's CMO/CDMO business revenue continues to grow rapidly.

In terms of research and development, in the first half of the year, the company continued to increase research and development efforts in fluid chemistry, enzyme catalysis, crystallization, micronization, preparation and separation, peptides and oligonucleoside drugs, and increased investment in research and clinical trials ( And commercialization) The process of the phase project, the investment in the research and development of new products and new technology platforms has been significantly increased, and the investment in research and development has increased significantly. The company plans to continue investing in research and development of new technology platforms in the second half of the year to build a leading position for future business growth. The basis of technical capabilities.

Recently, WuXi PharmaTech has taken a new action to start the Hong Kong stock market process. WuXi PharmaTech said that having the 'A+H' dual financing platform will enable investors and customers at home and abroad to understand the company more intuitively and quickly, effectively establishing the company globally. The image of the capital market will quickly enhance the company's international reputation; at the same time, it will provide strong capital support for the rapid and healthy development in the future, which will enable the company's global business to develop faster and better.

With the successful conclusion of WuXi PharmaTech's 'One Demolition Three' listing, the market value of the three listed companies has also steadily increased. As of September 26, the total market value of WuXi PharmaTech was 93 billion yuan, and the total market value of Yaoming Bio was 94.8 billion Hong Kong dollars. The total market value of the whole pharmaceutical industry is 18 billion yuan.

The actual controller of Chengda Bio is the State-owned Assets Supervision and Administration Commission of the People's Government of Liaoning Province. Its main business is research and development, production and sales of human vaccines. The main products for sale include human rabies vaccine (Vero cells), freeze-dried human rabies. Vaccine (Vero cells), human brain inactivated vaccine (Vero cells), freeze-dried JE inactivated vaccine (Vero cells), the main source of income is the production and sale of human vaccines. In the first half of the year, the company's operating income was 66,561.96. Ten thousand yuan, a year-on-year increase of 13.86%; attributable net profit of 295,946,400 yuan, an increase of 14.20%, deducting non-net profit of 291,137,900 yuan, an increase of 13.10%.

Chengda Bio has a relatively complete product pipeline, and the products under development are progressing in an orderly manner. The bivalent renal syndrome hemorrhagic fever vaccine (Vero cells) is prepared to declare the production number; in addition, there are four kinds of research products that have obtained clinical trial approvals for drugs. They are hepatitis A inactivated vaccine (human diploid cells), tetravalent influenza virus split vaccine, group A group C meningococcal polysaccharide conjugate vaccine, Haemophilus influenzae type b conjugate vaccine. In addition, other products under research R&D includes joint vaccine development and joint development with innovative vaccines from foreign R&D institutions. Recently, Chengda Biotech announced that freeze-dried humans use rabies vaccine (human diploid cells) to obtain clinical trial approvals.

In July of this year, the event of longevity biological vaccine attracted great attention from all walks of life. For the potential risks caused by the safety of vaccine products, Chengda said that the company has more than 70 million experience at home and abroad, and there are no major safety accidents. The company will continue to improve the quality management of vaccine production, strengthen the construction of sales and marketing network, strengthen the monitoring of cold chain transportation, improve and improve the vaccine adverse reaction management system, ensure that products can be traced back to every vaccinated end customer, and protect consumers. Safe to use, to provide consumers with reliable quality vaccine products.

Source: Listed company announcement